Immunocore to Present Phase 1 Data at 2026 SITC Meeting
The company plans to present Phase 1 data for brenetafusp plus KIMMTRAK in metastatic uveal melanoma during a late-breaking oral session.
Related stories
Federated Hermes Reports Quarterly Results
Federated Hermes reported results for the quarter ended September 30.
M impact | EQUITY | Oct 29, 2026, 11:21 PM UTC
Gaming and Leisure Properties Reports Quarterly Results
Gaming and Leisure Properties reported results for the quarter ended September 30.
M impact | EQUITY | Oct 29, 2026, 11:21 PM UTC
Invesco Mortgage Capital Reports Quarterly Results
Invesco Mortgage Capital reported results for the quarter ended September 30; no figures were provided.
M impact | EQUITY | Oct 29, 2026, 11:21 PM UTC
Stocks in Australia Hit 7-week High
ASX200 increased to 8937.00 Index Points, the highest since September 2026. Over the past 4 weeks, Australia Stock Market Index (AU200) gained 1.64%, and in the last 12 months, it
L impact | EQUITY | Oct 29, 2026, 11:21 PM UTC
Schneider National Reports Quarterly Results for Period Ended September 30
Schneider National reported results for the quarter ended September 30. The supplied summary does not include the results figures.
M impact | EQUITY | Oct 29, 2026, 11:20 PM UTC
Vamos Q3 net profit at 151 million reais
Vamos reported Q3 net profit of 151 million reais, versus the IBES estimate of 134 million reais.
M impact | EQUITY | Oct 29, 2026, 11:18 PM UTC